Literature DB >> 23524883

Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.

Louise Scharf1, Anthony P West, Han Gao, Terri Lee, Johannes F Scheid, Michel C Nussenzweig, Pamela J Bjorkman, Ron Diskin.   

Abstract

Efforts to design an effective antibody-based vaccine against HIV-1 would benefit from understanding how germ-line B-cell receptors (BCRs) recognize the HIV-1 gp120/gp41 envelope spike. Potent VRC01-like (PVL) HIV-1 antibodies derived from the VH1-2*02 germ-line allele target the conserved CD4 binding site on gp120. A bottleneck for design of immunogens capable of eliciting PVL antibodies is that VH1-2*02 germ-line BCR interactions with gp120 are uncharacterized. Here, we report the structure of a VH1-2*02 germ-line antibody alone and a germ-line heavy-chain/mature light-chain chimeric antibody complexed with HIV-1 gp120. VH1-2*02 residues make extensive contacts with the gp120 outer domain, including all PVL signature and CD4 mimicry interactions, but not critical CDRH3 contacts with the gp120 inner domain and bridging sheet that are responsible for the improved potency of NIH45-46 over closely related clonal variants, such as VRC01. Our results provide insight into initial recognition of HIV-1 by VH1-2*02 germ-line BCRs and may facilitate the design of immunogens tailored to engage and stimulate broad and potent CD4 binding site antibodies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23524883      PMCID: PMC3625305          DOI: 10.1073/pnas.1303682110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.

Authors:  Anthony P West; Ron Diskin; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-27       Impact factor: 11.205

2.  Progress in the rational design of an AIDS vaccine.

Authors:  Gary J Nabel; Peter D Kwong; John R Mascola
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

3.  Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Authors:  Johannes F Scheid; Hugo Mouquet; Beatrix Ueberheide; Ron Diskin; Florian Klein; Thiago Y K Oliveira; John Pietzsch; David Fenyo; Alexander Abadir; Klara Velinzon; Arlene Hurley; Sunnie Myung; Farid Boulad; Pascal Poignard; Dennis R Burton; Florencia Pereyra; David D Ho; Bruce D Walker; Michael S Seaman; Pamela J Bjorkman; Brian T Chait; Michel C Nussenzweig
Journal:  Science       Date:  2011-07-14       Impact factor: 47.728

4.  Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.

Authors:  Milena Veselinovic; C Preston Neff; Leila R Mulder; Ramesh Akkina
Journal:  Virology       Date:  2012-07-24       Impact factor: 3.616

5.  B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.

Authors:  Barton F Haynes; Garnett Kelsoe; Stephen C Harrison; Thomas B Kepler
Journal:  Nat Biotechnol       Date:  2012-05-07       Impact factor: 54.908

Review 6.  Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.

Authors:  Dennis R Burton; Pascal Poignard; Robyn L Stanfield; Ian A Wilson
Journal:  Science       Date:  2012-07-13       Impact factor: 47.728

7.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

Review 8.  The changing face of HIV vaccine research.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  J Int AIDS Soc       Date:  2012-07-05       Impact factor: 5.396

9.  Antibody-based protection against HIV infection by vectored immunoprophylaxis.

Authors:  Alejandro B Balazs; Joyce Chen; Christin M Hong; Dinesh S Rao; Lili Yang; David Baltimore
Journal:  Nature       Date:  2011-11-30       Impact factor: 49.962

10.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962

View more
  33 in total

1.  Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.

Authors:  Shannon R Esswein; Harry B Gristick; Andrea Jurado; Avery Peace; Jennifer R Keeffe; Yu E Lee; Alisa V Voll; Mohsan Saeed; Michel C Nussenzweig; Charles M Rice; Davide F Robbiani; Margaret R MacDonald; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-22       Impact factor: 11.205

Review 2.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 3.  Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.

Authors:  Ivelin S Georgiev; M Gordon Joyce; Tongqing Zhou; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

4.  Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site.

Authors:  Simone Conti; Kevin J Kaczorowski; Ge Song; Katelyn Porter; Raiees Andrabi; Dennis R Burton; Arup K Chakraborty; Martin Karplus
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

Review 5.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

6.  Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.

Authors:  Ujjwal Rathore; Piyali Saha; Sannula Kesavardhana; Aditya Arun Kumar; Rohini Datta; Sivasankar Devanarayanan; Raksha Das; John R Mascola; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

7.  Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.

Authors:  Ujjwal Rathore; Mansi Purwar; Venkada Subramanian Vignesh; Raksha Das; Aditya Arun Kumar; Sanchari Bhattacharyya; Heather Arendt; Joanne DeStefano; Aaron Wilson; Christopher Parks; Celia C La Branche; David C Montefiori; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

8.  Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies.

Authors:  Thaddeus M Davenport; Jason Gorman; M Gordon Joyce; Tongqing Zhou; Cinque Soto; Miklos Guttman; Stephanie Moquin; Yongping Yang; Baoshan Zhang; Nicole A Doria-Rose; Shiu-Lok Hu; John R Mascola; Peter D Kwong; Kelly K Lee
Journal:  Structure       Date:  2016-07-28       Impact factor: 5.006

9.  Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign.

Authors:  Karen Tran; Christian Poulsen; Javier Guenaga; Natalia de Val; Natalia de Val Alda; Richard Wilson; Christopher Sundling; Yuxing Li; Robyn L Stanfield; Ian A Wilson; Andrew B Ward; Gunilla B Karlsson Hedestam; Richard T Wyatt
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

10.  Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.

Authors:  Hongying Duan; Xuejun Chen; Jeffrey C Boyington; Cheng Cheng; Yi Zhang; Alexander J Jafari; Tyler Stephens; Yaroslav Tsybovsky; Oleksandr Kalyuzhniy; Peng Zhao; Sergey Menis; Martha C Nason; Erica Normandin; Maryam Mukhamedova; Brandon J DeKosky; Lance Wells; William R Schief; Ming Tian; Frederick W Alt; Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2018-07-31       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.